DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications. We continue to closely monitor the FDA landscape to help provide our audiences with an understanding of the current drug and biologic market.
*Today, we are CarelonRx, but when we created some of these documents, we were IngenioRx. This name change doesn't impact our dedication to driving cost savings, personalizing customer experiences, and improving whole-person health.
